Influenza virus neuraminidase (NA) has emerged as a promising vaccine candidate due to its relatively stable antigenic structure and the ability of NA-specific antibodies to provide cross-protection within influenza virus subtypes. Since the influenza virus causes respiratory infections in humans, developing mucosal vaccines to protect the entry site of the virus is of high importance. Recombinant NA requires adjuvants to induce a protective immune response after mucosal administration. In the current study, we analyze the immunogenicity and protective efficacy of a recombinant NA-based influenza virus vaccine administered intranasally in combination with adjuvants consisting of outer membrane proteins from Neisseria meningitidis complexed with exogenous lipopolysaccharides (LPS) from Shigella flexneri or endogenous LPS from N. meningitidis. We evaluated the local and systemic humoral and cellular immune responses to adjuvanted recombinant N1 NA, analyzing the dynamics of local follicular T-helper (Tfh) cells and germinal center B cells (GCB) in nasal-associated lymphoid tissue (NALT) and tissue-resident memory T cells in lungs, as well as the levels of IgA and IgG in the upper and lower respiratory tracts. Finally, we performed a heterologous challenge study to test the ability of the investigated vaccine formulations to induce cross-protection. The study demonstrates that bacterial cell membrane-derived adjuvants significantly improve the immunogenicity and protective efficacy of the recombinant N1 NA-based influenza vaccine leading to protection against clade 2.3.4.4b H5N1 challenge. This finding supports the potential of these adjuvanted vaccines in providing effective mucosal immunity against influenza virus.